Uterine Adenomyosis – A Complete Patient Guide

Overview

Adenomyosis is a benign (non‑cancerous) condition in which the inner lining of the uterus (the endometrium) grows into the muscular wall of the uterus (the myometrium). This infiltration causes the uterus to become enlarged and can lead to heavy, painful periods and chronic pelvic discomfort.

Who it affects

• Women of reproductive age, most commonly between 35 and 50 years old.
• It is rare in teenagers and women who have not yet had a period (menarche).
• Women who have had multiple full‑term pregnancies (parity) appear to have a slightly higher risk.

Prevalence

• Population‑based studies estimate that adenomyosis affects 10–20 % of women of reproductive age, but many cases go undiagnosed because symptoms overlap with other gynecologic disorders.¹
• Among women undergoing hysterectomy for benign disease, up to 30 % have histologic evidence of adenomyosis.²

Symptoms

Symptoms can be mild or severe and may vary throughout the menstrual cycle.

Primary symptoms

• Heavy menstrual bleeding (menorrhagia): Soaking through one or more pads or tampons every hour, passing clots larger than a quarter.
• Severe menstrual cramps (dysmenorrhea): Pain that begins before bleeding starts and can last several days.
• Chronic pelvic pain: A dull or aching pressure that persists between periods.
• Dyspareunia: Pain during or after intercourse, often deep‑penetrating.
• Enlarged, tender uterus: May be felt during a pelvic exam.

Secondary / less common symptoms

• Irregular spotting or bleeding between periods.
• Fatigue or iron‑deficiency anemia caused by chronic blood loss.
• Infertility or difficulty conceiving (reported in 10–15 % of affected women).³
• Bladder pressure or urinary frequency if the uterus presses on the bladder.

Causes and Risk Factors

The exact cause of adenomyosis is still being studied, but several theories have strong supporting evidence.

Proposed mechanisms

1. Invagination theory: The endometrial tissue may be forced into the myometrium through tiny breaks in the junctional zone.
2. De Novo development: Stem‑like cells within the myometrium differentiate into endometrial tissue.
3. Hormonal influence: Estrogen stimulates growth of ectopic endometrial cells; adenomyosis tissue often shows higher estrogen‑receptor activity than normal myometrium.

Risk factors

• Age 35‑50: Peak incidence occurs in this range.
• Previous uterine surgery: C‑section, myomectomy, or dilation & curettage may disrupt the endometrial‑myometrial boundary.
• High parity: Women who have given birth to three or more children have a modestly increased risk.
• Other uterine conditions: Endometriosis, fibroids, or chronic inflammation may coexist.
• Hormonal factors: Early menarche (< 12 years) and prolonged exposure to estrogen (e.g., obesity) can contribute.

Diagnosis

Because symptoms overlap with fibroids, endometriosis, and other causes of heavy bleeding, a systematic approach is essential.

Clinical evaluation

• Medical history: Detailed menstrual, obstetric, and surgical history.
• Physical exam: Bimanual pelvic exam may reveal a uniformly enlarged, tender uterus.

Imaging studies

1. Transvaginal ultrasound (TVUS): First‑line imaging. Typical findings include a heterogeneous myometrium, “globular” uterine shape, and “myometrial cysts.” Sensitivity 70–80 % and specificity ~85 %.⁴
2. Magnetic resonance imaging (MRI): Gold standard for non‑invasive diagnosis. High‑resolution T2‑weighted images show thickening of the junctional zone (>12 mm) and small high‑signal foci representing ectopic endometrium.
3. 3‑D ultrasound: Emerging technique with accuracy comparable to MRI in experienced hands.

Definitive diagnosis

• Histopathologic examination of uterine tissue (usually after hysterectomy) remains the definitive test, showing endometrial glands and stroma within the myometrium.

When to refer

• If imaging is inconclusive and symptoms are severe, referral to a gynecologist specializing in minimally invasive surgery or reproductive endocrinology is advisable.

Treatment Options

Management is individualized based on symptom severity, desire for future fertility, age, and overall health.

Medical (non‑surgical) therapy

1. Hormonal contraceptives (combined oral pills, patch, vaginal ring): Suppress ovulation and reduce menstrual flow; useful for mild‑moderate pain.
2. Levonorgestrel intrauterine system (LNG‑IUS, e.g., Mirena): Releases progestin locally, decreasing bleeding by up to 90 % and often improving pain within 3–6 months.⁵
3. Progestin therapy (oral medroxyprogesterone acetate, depot‑medroxyprogesterone acetate): Systemic progestins can shrink ectopic tissue.
4. Gonadotropin‑releasing hormone (GnRH) agonists/antagonists: Induce a reversible hypo‑estrogenic state, providing symptom relief for 3–6 months. Use is limited by bone‑density loss and menopausal‑type side effects.
5. Tranexamic acid: Antifibrinolytic that reduces menstrual blood loss; does not treat pain.
6. Non‑steroidal anti‑inflammatory drugs (NSAIDs): First‑line for dysmenorrhea; may need higher doses for adequate pain control.

Surgical options

• Uterine‑sparing procedures
  • Hysteroscopic endometrial ablation: Destroys the endometrial lining; best for women who no longer desire fertility.
  • Laparoscopic adenomyomectomy: Excision of adenomyotic tissue while preserving uterine integrity; technically demanding and carries a risk of uterine rupture in future pregnancies.
  • Uterine artery embolization (UAE): Interventional radiology technique that blocks blood flow to adenomyotic tissue, reducing size and bleeding. Success rates 70–85 % for symptom relief.⁶
• Definitive procedure – Hysterectomy
  • Removal of the uterus eliminates the disease permanently. Recommended for women who have completed childbearing and have refractory symptoms.
  • Can be performed vaginally, laparoscopically, or via robotic assistance.

Lifestyle and adjunctive measures

• Regular aerobic exercise may reduce menstrual pain by improving pelvic circulation.
• Heat therapy (warm packs, heating pads) applied to lower abdomen during cramps.
• Dietary omega‑3 fatty acids (found in fish, flaxseed) have modest anti‑inflammatory effects.

Living with Uterine Adenomyosis

Daily management tips

• Track your cycle: Use a period‑tracking app to record flow, pain scores, and medication response. This data helps your provider adjust treatment.
• Pain‑relief plan: Have an NSAID on hand 30–45 minutes before expected cramps; combine with a heating pad for synergistic relief.
• Iron intake: Because chronic bleeding can cause anemia, include iron‑rich foods (red meat, lentils, fortified cereals) and consider an iron supplement after discussing with your doctor.
• Sexual comfort: Use a water‑based lubricant and experiment with positions that reduce deep‑penetration pressure if dyspareunia is an issue.
• Stress management: Chronic pelvic pain can heighten stress; practices such as mindfulness, yoga, or CBT have shown benefit for menstrual‑related pain.
• Regular follow‑ups: Even if symptoms improve, schedule a yearly check‑up to reassess uterine size and rule out co‑existing pathology (e.g., fibroids).

Fertility considerations

If you are trying to conceive, discuss with a reproductive specialist. Options may include:

• Short‑course GnRH agonist therapy before in‑vitro fertilization (IVF) to improve implantation rates.
• Laparoscopic adenomyomectomy in selected cases, followed by a 6‑month healing period before attempting pregnancy.

Prevention

Because the exact cause is unknown, specific prevention is challenging, but certain strategies may lower risk:

• Maintain a healthy weight (BMI < 25) to reduce excess estrogen production from adipose tissue.
• Limit exposure to environmental estrogens (e.g., certain plastics, pesticide residues) where possible.
• Promptly treat severe uterine infections or postpartum retained tissue to avoid chronic inflammation.
• Consider discussing the risks of unnecessary uterine surgeries (e.g., repeated curettage) with your physician.

Complications

If left untreated or poorly managed, adenomyosis can lead to:

• Severe anemia: Chronic heavy bleeding may require transfusion.
• Infertility or recurrent pregnancy loss: Distorted uterine architecture can impair implantation.
• Pelvic inflammatory disease (PID): Though rare, secondary infection of adenomyotic tissue can occur.
• Uterine rupture: Particularly after extensive adenomyomectomy; requires careful obstetric monitoring.
• Psychological impact: Chronic pain and bleeding can cause depression, anxiety, and reduced quality of life.

When to Seek Emergency Care

---

Sources:

1. Mayo Clinic. “Adenomyosis.” Updated 2023. https://www.mayoclinic.org
2. American College of Obstetricians and Gynecologists. “Practice Bulletin No. 227: Management of Adenomyosis.” 2021.
3. Vercellini P, et al. “Adenomyosis and infertility: a systematic review.” *Human Reproduction Update*, 2022.
4. NIH National Institute of Child Health & Human Development. “Uterine Adenomyosis Imaging.” 2022.
5. Lee JY, et al. “Effectiveness of levonorgestrel-releasing intrauterine system for adenomyosis.” *Fertility and Sterility*, 2021.
6. Gao Y, et al. “Uterine artery embolization for adenomyosis: long‑term outcomes.” *Radiology*, 2023.